Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies

Medicine & Life Sciences

• XL765 100%
• Rituximab 51%
• Sirolimus 50%
• Phosphatidylinositol 3-Kinase 48%
• B-Lymphocytes 36%
• Bendamustine Hydrochloride 36%
• Neoplasms 15%
• Maximum Tolerated Dose 11%
• Pharmacokinetics 10%
• Mantle-Cell Lymphoma 6%
• Febrile Neutropenia 5%
• Safety 5%
• B-Cell Chronic Lymphocytic Leukemia 5%
• B-Cell Lymphoma 4%
• Neutropenia 4%
• Non-Hodgkin's Lymphoma 4%
• Thrombocytopenia 4%
• Nausea 4%
• Headache 4%
• Fatigue 4%
• Anemia 4%
• Fever 3%